AUA: Atenolol Linked to Drop in Low-, Intermediate-Risk Prostate Cancer

FRIDAY, May 3, 2019 -- Atenolol is associated with a reduction in incident intermediate- and low-risk prostate cancer (PCa), according to a study presented at the annual meeting of the American Urological Association, held from May 3 to 6 in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

A couple of years ago a team of U.S. and U.K. scientists came up with a way of making molecular motors that can drill through cancer cells, destroying them in the process. The researchers, from Rice University, Durham University, and North Carolina S...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Nanomedicine Oncology Source Type: blogs
CONCLUSIONS The present results suggest that targeting of PLCε/BMP-6/SMAD signaling may increase the sensitivity of CRPC to AR antagonists and inhibit tumor progression. PMID: 31201297 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
An analysis of the ARAMIS trial looked at quality of life and other outcomes with darolutamide in men with nonmetastatic castration-resistant prostate cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
You are leaving AARP.org and going to the website of our trusted provider. ... The provider ’s terms, conditions and policies apply. ... Please return to AARP.org to learn more about other benefits.
Source: AARP.org News - Category: American Health Source Type: news
ConclusionOur study does not support reduced cancer mortality among anticoagulant users. Future studies on drug use and cancer mortality should be adjusted for anticoagulants as they are associated with significantly higher risk of cancer death.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Conclusions: Mipsagargin is relatively well tolerated and promotes prolonged disease stabilization in patients with advanced HCC that had progressed on prior treatment with sorafenib. A significant decrease in Ktrans upon treatment suggests mipsagargin reduces blood flow in hepatic lesions.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractThe role of DNA MMR genes in prostate cancer (PrCa) is controversial, as genetic alterations leading to microsatellite instability are incompletely defined in these tumors.ERG rearrangements andPTEN loss are concomitant events in PrCa. The aim of this study has been to analyze the immunohistochemical (IHC) expression of MSH2, MSH6, MLH1, PMS2, ERG, and PTEN and their potential association with the grade group (GG) grading system (WHO 2016) and PSA recurrence in a series of 200 PrCa (PSMAR-Biobank, Barcelona, Spain). MSH2, MLH1, PMS2, and PTEN losses were documented in 8%, 5%, 2%, and 36.5%, respectively. ERG expres...
Source: Virchows Archiv - Category: Pathology Source Type: research
Gonadotropin-releasing hormone (GnRH) has been demonstrated to exert anti-proliferative effects on various tumour cells in ovarian, endometrial, bladder, and prostate cancer as a part of the autocrine system. In addition, the expression of GnRH and its receptor has been identified in breast cancer and non-reproductive cancers, such as pancreatic cancer and glioblastoma. Previous studies have reported abnormal GnRH expression in several malignant tumours, suggesting that GnRH and its receptor might be essential for tumourigenesis. In the present study, we attempted to clarify the mechanisms underlying GnRH function in cell ...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Publication date: 1 October 2019Source: Sensors and Actuators B: Chemical, Volume 296Author(s): Chammari Pothipor, Natta Wiriyakun, Thitirat Putnin, Aroonsri Ngamaroonchote, Jaroon Jakmunee, Kontad Ounnunkad, Rawiwan Laocharoensuk, Noppadol AroonyadetAbstractRecent studies show that electrochemical biosensors offer simple, robust and low-cost solution for point-of-care applications. To meet rigorous requirements of early disease diagnosis and other medical applications, nanomaterials have been investigated to increase sensitivity and selectivity of electrochemical sensors. Herein, we successfully developed graphene-poly(3-...
Source: Sensors and Actuators B: Chemical - Category: Chemistry Source Type: research
Publication date: Available online 15 June 2019Source: European UrologyAuthor(s): Noel Clarke, Heather Payne, Jan van der Meulen
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Atenolol | Cancer | Cancer & Oncology | Pharmaceuticals | Prostate Cancer | Study | Urology & Nephrology